Last Updated: September 28, 2026

Endo Pharms Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ENDO PHARMS

ENDO PHARMS has ten approved drugs.

There are three US patents protecting ENDO PHARMS drugs.

Summary for Endo Pharms

US Patents:	3
Tradenames:	7
Ingredients:	5
NDAs:	10

Drugs and US Patents for Endo Pharms

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-007	Dec 9, 2011		DISCN	Yes	No	7,851,482	⤷ Start Trial		Y		⤷ Start Trial
Endo Pharms	VALPIN 50	anisotropine methylbromide	TABLET;ORAL	013428-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-002	Dec 9, 2011		DISCN	Yes	No	7,851,482	⤷ Start Trial		Y		⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-004	Dec 9, 2011		DISCN	Yes	No	8,808,737	⤷ Start Trial				⤷ Start Trial
Endo Pharms	NUMORPHAN	oxymorphone hydrochloride	SUPPOSITORY;RECTAL	011738-004	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-001	Dec 9, 2011		DISCN	Yes	No	7,851,482	⤷ Start Trial		Y		⤷ Start Trial
Endo Pharms	OPANA	oxymorphone hydrochloride	TABLET;ORAL	021611-002	Jun 22, 2006		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Endo Pharms

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-006	Dec 9, 2011	8,114,383	⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-003	Dec 9, 2011	8,329,216	⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-005	Dec 9, 2011	8,329,216	⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-003	Dec 9, 2011	8,114,383	⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-004	Dec 9, 2011	8,309,060	⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-001	Dec 9, 2011	8,192,722	⤷ Start Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-005	Dec 9, 2011	8,309,060	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ENDO PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-05-29
➤ Subscribe	Extended-release Tablets	5 mg, 10 mg, 20 mg and 40 mg	➤ Subscribe	2007-11-23
➤ Subscribe	Extended-release Tablets	30 mg	➤ Subscribe	2008-06-12

International Patents for Endo Pharms Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	2009528366	⤷ Start Trial
Mexico	2009006283	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2008072018	⤷ Start Trial
Japan	2010513260	⤷ Start Trial
Mexico	2008010921	⤷ Start Trial
Russian Federation	2422445	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2007103105	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.